Nant cancer vaccine
US-2020171137-A1 · Jun 4, 2020 · US
Intratumorally injected yeast vaccine
US12558408B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12558408-B2 |
| Application number | US-202318179907-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 7, 2023 |
| Priority date | Mar 8, 2022 |
| Publication date | Feb 24, 2026 |
| Grant date | Feb 24, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are compositions and methods for treating solid tumors with yeast-based formulations.
First claim
Opening claim text (preview).
What is claimed is: 1 . A composition for injection into a solid tumor, wherein the composition comprises effective amounts of a yeast and/or a lysate thereof, a checkpoint inhibitor selected from the group consisting of an anti-CTLA-4 antibody and an anti-PDL1 antibody, and an immunostimulatory protein selected from the group consisting of an Ox40 receptor agonist and nogapendkin-alfa-inbakicept (NAI; N-803). 2 . The composition of claim 1 , wherein the yeast is Saccharomyces cerevisiae. 3 . The composition of claim 1 , wherein the yeast is genetically engineered to express a tumor associated antigen, tumor specific antigen, or a neoepitope. 4 . The composition of claim 1 , wherein the Ox40 receptor agonist is a monoclonal antibody or a receptor ligand. 5 . The composition of claim 1 , wherein the tumor is a mucosal tumor, melanoma, a lung tumor or a colorectal tumor. 6 . The composition of claim 1 , wherein the tumor is metastatic. 7 . The composition of claim 1 , wherein the yeast is genetically engineered to express protein G on the surface of the yeast. 8 . The composition of claim 7 , wherein the Ox40 receptor agonist is an Fc-agonist fusion protein, and wherein the Fc-agonist fusion protein is bound to the yeast prior to administration. 9 . A method of treating a solid tumor, the method comprising intratumoral injection of an effective amount of a composition comprising a yeast and/or a lysate thereof, a checkpoint inhibitor selected from the group consisting of an anti-CTLA-4 antibody and an anti-PDL1 antibody, and an immunostimulatory protein selected from the group consisting of an Ox40 receptor agonist and nogapendkin-alfa-inbakicept (NAI; N-803). 10 . The method of claim 9 , wherein the yeast is Saccharomyces cerevisiae. 11 . The method of claim 9 , wherein the yeast is genetically engineered to express a tumor associated antigen, tumor specific antigen, or a neoepitope. 12 . The method of claim 9 , wherein the Ox40 receptor agonist is a monoclonal antibody or a receptor ligand. 13 . The method of claim 9 , wherein the tumor is a mucosal tumor, melanoma, a lung tumor or a colorectal tumor. 14 . The method of claim 9 , wherein the tumor is metastatic. 15 . The method of claim 9 , wherein the yeast is genetically engineered to express protein G on the surface of the yeast. 16 . The method of claim 15 , wherein the Ox40 receptor agonist is an Fc-agonist fusion protein, and wherein the Fc-agonist fusion protein is bound to the yeast prior to administration.
Assignees
Inventors
Classifications
against B7 molecules, e.g. CD80, CD86 · CPC title
comprising antibodies · CPC title
against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241) · CPC title
against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title
characterised by the dose, timing or administration schedule · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12558408B2 cover?
- Disclosed herein are compositions and methods for treating solid tumors with yeast-based formulations.
- Who is the assignee on this patent?
- Immunitybio Inc
- What technology area does this patent fall under?
- Primary CPC classification A61P35/04. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).